Amphastar PharmaceuticalsAMPH -6.89%83 Buyback Yield % is 9.80 as of Jun. 29, 2026, which is 283% above its 10-year median of 2.56. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 292 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 97.6% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Buyback Yield % of 9.80 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Amphastar Pharmaceuticals and its competitors. This is 283% above median its historical median of 2.56. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #7 out of 292 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Amphastar Pharmaceuticals' Buyback Yield % too high?
Amphastar Pharmaceuticals' current Buyback Yield % of 9.80 is 283% above median its 10-year median of 2.56. Based on the distribution chart, Amphastar Pharmaceuticals ranks #7 out of 292 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Buyback Yield % compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #7 out of 292 companies for Buyback Yield %. This places Amphastar Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Buyback Yield % is 9.80, which is 283% above median its own 10-year median of 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $20.28 — trading 58.4% below its estimated fair value. The current Buyback Yield % is 9.80, which is 283% above median its 10-year median of 2.56. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Buyback Yield % is 9.80 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.28 is trading 58.4% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Buyback Yield %: 9.80 (283% above median its 10-year median of 2.56)
GF Value™: $48.79 vs. price of $20.28 (58.4% below fair value)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
